Arcutis Biotherapeutics shareholders re-elect three Class II directors, ratify EY, approve say-on-pay

Arcutis Biotherapeutics, Inc.

All three Class II directors elected: Heron (44.2M for), Krishnamohan (50.4M for), Watanabe (45.4M for).
Ratification of Ernst & Young as independent auditor for FY 2023 passed with 54.5M votes for, 358K against.
Non-binding advisory vote on named executive officer compensation approved with 43.8M for, 7.3M against.
Meeting held May 31, 2023; record date April 3, 2023 with 61,360,936 shares outstanding.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arcutis Biotherapeutics, Inc. shareholders approved Election of three Class II directors to hold office until the 2026 annual meeting or until their respective successor is elected at the 2023-05-31 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-31

Exact text from the filing

Proposal 1. The election of three Class II directors to hold office until the 2026 annual meeting of stockholders or until their respective successor is elected: Nominee Votes for Votes withheld Broker Non-Votes Patrick J. Heron 44,208,982 6,933,977 3,771,693 Neha Krishnamohan 50,425,906 717,053 3,771,693 Todd Franklin Watanabe 45,416,267 5,726,692 3,771,693

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arcutis Biotherapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers at the 2023-05-31 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-05-31

Exact text from the filing

Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers: Votes for Votes against Abstentions Broker Non-Votes 43,770,313 7,343,874 28,772 3,771,693

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arcutis Biotherapeutics, Inc. shareholders approved Ratification of the selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-31 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-31

Exact text from the filing

Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023: Votes for Votes against Abstentions Broker Non-Votes 54,541,027 358,765 14,860 —

View on SEC.gov

Browse all shareholder votes →

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001787306-23-000068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.